Guardian Pharmacy Services (NYSE:GRDN) versus Ironwood Pharmaceuticals (NASDAQ:IRWD) Critical Comparison

Guardian Pharmacy Services (NYSE:GRDN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Guardian Pharmacy Services and Ironwood Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardian Pharmacy Services	$1.45 billion	1.44	$49.22 million	$0.83	50.34
Ironwood Pharmaceuticals	$296.15 million	2.27	$24.02 million	$0.60	6.88

Guardian Pharmacy Services has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Guardian Pharmacy Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Guardian Pharmacy Services and Ironwood Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardian Pharmacy Services	0	2	7	0	2.78
Ironwood Pharmaceuticals	1	3	2	1	2.43

Guardian Pharmacy Services currently has a consensus target price of $42.83, suggesting a potential upside of 2.51%. Ironwood Pharmaceuticals has a consensus target price of $6.23, suggesting a potential upside of 50.93%. Given Ironwood Pharmaceuticals’ higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Guardian Pharmacy Services.

Profitability

This table compares Guardian Pharmacy Services and Ironwood Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guardian Pharmacy Services	3.64%	30.72%	15.99%
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%

Risk & Volatility

Guardian Pharmacy Services has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.

Summary

Guardian Pharmacy Services beats Ironwood Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.